The Max Foundation and BeiGene partner for CLL treatment in LMICs

The Max Foundation shared a post by BeiGene on LinkedIn:

“We’re grateful for the opportunity to talk with Melika Davis and BeiGene about CLL, and why it’s important for patients to have access to treatment no matter where they live.”

Quoting BeiGene’s post:

“In alignment with our commitment to advancing global health equity, we’re partnering with The Max Foundation to bring our innovative medicine to patients with chronic lymphocytic leukemia (CLL) in low- and middle-income countries.

Last week, we were honored to welcome Pat Garcia-Gonzalez, CEO of The Max Foundation, Cathy Scheepers, Region Head for Africa at The Max Foundation, and Dr. Fisihatsion Tadesse, an Ethiopian hematologist.

They joined Melika Davis, our Head of Global Clinical Operations, in a profound discussion on the challenges of CLL treatment in Ethiopia. Our collaboration with The Max Foundation stands as a crucial step in addressing the pressing needs of patients and clinics across the country.

Watch the video to learn more.”

Source: The Max Foundation/LinkedIn and BeiGene/LinkedIn